- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of February 4
The Center for Biosimilars® recaps the top news for the week of February 4, 2019.
Transcript:
Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of February 4.
Number 5: Fresenius Kabi announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion for its biosimilar adalimumab.
Number 4: In a recent paper, Italian rheumatology providers called into question whether newly published results from the DANBIO registry can be used to guide non-medical switching.
Number 3: Researchers have provided detailed results from the phase 3 REFLECTIONS trial that found Pfizer's trastuzumab biosimilar to be equivalent to the EU reference.
Number 2: A recent white paper found that the assumption that Medicare Part B payment rates lead providers choose costlier treatments in order to benefit from larger add-on payments is incorrect.
Number 1: Mundipharma announced that it has launched Pelmeg, a biosimilar pegfilgrastim, in Germany, the Netherlands, and Ireland.
Finally, last week, our e-newsletter asked if drug makers should be required to disclose their research and development costs.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Eye on Pharma: EU Aflibercept Approvals; Biosimilars Canada Campaign; Celltrion Data
November 19th 2024The European Commission grants marketing authorization to 2 aflibercept biosimilars; Biosimilars Canada launches new campaign to provide sustainable solutions to employers; Celltrion shares positive data for 2 biosimilars.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Breaking Down Biosimilar Barriers: Interchangeability
November 14th 2024Part 3 of this series for Global Biosimilars Week, penned by Dracey Poore, director of biosimilars at Cardinal Health, explores the critical topic of interchangeability, examining its role in shaping biosimilar adoption and the broader implications for accessibility.
